Commitments and Contingencies (Details) £ in Millions |
3 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|
Apr. 03, 2024 |
Aug. 31, 2025
USD ($)
|
May 31, 2025
USD ($)
item
|
May 31, 2025
GBP (£)
|
|
| Side Letter Agreement With Samsung | ||||
| Commitments and Contingencies | ||||
| Contractual obligation, percentage of qualifying revenue agreed to pay | 20.00% | 20.00% | ||
| Amount of contractual obligation included in other liabilities | $ 43,600,000 | $ 43,600,000 | ||
| Progenics Purchase Agreement | ||||
| Commitments and Contingencies | ||||
| Amount of milestone payments payable | $ 5,000,000 | |||
| Percentage of royalty payable | 3.50% | |||
| Amount payable upon filing BLA with FDA | $ 500,000 | |||
| Amount payable upon FDA approval | 500,000 | |||
| Annual maintenance fees | $ 150,000 | |||
| Progenics Purchase Agreement | Royalty Payable in Initial 10 Years | ||||
| Commitments and Contingencies | ||||
| Percentage of royalty payable | 5.00% | |||
| Lonza Agreement | ||||
| Commitments and Contingencies | ||||
| Number of contract manufacturers | item | 2 | |||
| Annual license fee | $ 350,000 | £ 0.3 | ||
| Royalty on net sales (as a percent) | 2.00% | 2.00% |
| X | ||||||||||
- Definition Amount payable upon FDA approval. No definition available.
|
| X | ||||||||||
- Definition Amount payable upon filing BLA with FDA. No definition available.
|
| X | ||||||||||
- Definition Amount of annual maintenance fees. No definition available.
|
| X | ||||||||||
- Definition Amount of milestone payments payable. No definition available.
|
| X | ||||||||||
- Definition Percentage of royalty payable. No definition available.
|
| X | ||||||||||
- Definition Amount of contractual obligation excluding non-contingent amount. No definition available.
|
| X | ||||||||||
- Definition Percentage of qualifying revenue generated in each calendar year based on which payment to be made for the contractual obligation due. No definition available.
|
| X | ||||||||||
- Definition The amount of annual license fee payable under the license agreement. No definition available.
|
| X | ||||||||||
- Definition The number of contract manufacturers. No definition available.
|
| X | ||||||||||
- Definition Potential royalty payment as percentage of net sales. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|